4.6 Article

A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites

Journal

MICROBIOLOGY SPECTRUM
Volume 9, Issue 2, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/Spectrum.00274-21

Keywords

antimalarials; 2-amino-6-phenyl-thienopyrimidin-4(3H)-one; multistage activity; artemisinin resistance

Categories

Funding

  1. Fondation pour la Recherche Medicale (FRM Palukill) [DMC20181039565]
  2. Agence Nationale de la Recherche (ANR Plasmodrug) [18-CE18-0009-01]
  3. Centre National de la Recherche Scientifique (CNRS)
  4. Agence Nationale de la Recherche, France [ANR-17-CE13-0025-01]
  5. ANR [ANR-10-IAIHU-06, ANR-11-INBS-0011NeurATRIS]
  6. French government Program d'Investissements d'Avenir (PIA) [ANR-11-INBS-0008]

Ask authors/readers for more resources

This study presents a new chemical structure that is active against multiple stages of the human malaria parasite, including those resistant to artemisinins. The molecule also reduces transmission of the parasite to the mosquito vector in a mouse model. This new compound family shows promise for the development of novel antimalarial drugs with a unique multi-stage mechanism of action.
Human malaria infection begins with a one-time asymptomatic liver stage followed by a cyclic symptomatic blood stage. For decades, the research for novel anti-malarials focused on the high-throughput screening of molecules that only targeted the asexual blood stages. In a search for new effective compounds presenting a triple action against erythrocytic and liver stages in addition to the ability to block the transmission of the disease via the mosquito vector, 2-amino-thienopyrimidinone derivatives were synthesized and tested for their antimalarial activity. One molecule, named gamhepathiopine (denoted as M1 herein), was active at submicromolar concentrations against both erythrocytic (50% effective concentration [EC50] = 0.045 mM) and liver (EC50 = 0.45 mM) forms of Plasmodium falciparum. Furthermore, gamhepathiopine efficiently blocked the development of the sporogonic cycle in the mosquito vector by inhibiting the exflagellation step. Moreover, M1 was active against artemisinin-resistant forms (EC50 = 0.227 mM), especially at the quiescent stage. Nevertheless, in mice, M1 showed modest activity due to its rapid metabolization by P450 cytochromes into inactive derivatives, calling for the development of new parent compounds with improved metabolic stability and longer half-lives. These results highlight the thienopyrimidinone scaffold as a novel antiplasmodial chemotype of great interest to search for new drug candidates displaying multistage activity and an original mechanism of action with the potential to be used in combination therapies for malaria elimination in the context of artemisinin resistance. IMPORTANCE This work reports a new chemical structure that (i) displays activity against the human malaria parasite Plasmodium falciparum at 3 stages of the parasitic cycle (blood stage, hepatic stage, and sexual stages), (ii) remains active against parasites that are resistant to the first-line treatment recommended by the World Health Organization (WHO) for the treatment of severe malaria (artemisinins), and (iii) reduces transmission of the parasite to the mosquito vector in a mouse model. This new molecule family could open the way to the conception of novel antimalarial drugs with an original multistage mechanism of action to fight against Plasmodium drug resistance and block interhuman transmission of malaria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available